RxDoctor Payments Data

Nikunj Mehta, MD

Internal Medicine · Toms River, NJNPI 1821017344

Payments from drug & device makers

$2,455in general payments, 2019–2025

Across 169 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$836
  • AstraZeneca$447
  • Novo Nordisk$379
  • Lilly USA, LLC$314
  • Abbott$136
  • Eisai Inc.$56
  • plus $287 from 11 others

What the payments were for

  • Food & beverage$2,36196%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,455 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$378,192
Medicare patients
233
Services billed
5,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$78,038
TrulicityDulaglutide43$59,653
EliquisApixaban40$57,673
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$51,972
OzempicSemaglutide16$30,724
JanuviaSitagliptin Phosphate22$27,840
JanumetSitagliptin Phos/Metformin Hcl22$20,072
XareltoRivaroxaban11$14,475
FarxigaDapagliflozin Propanediol17$13,784
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,456
Atorvastatin Calcium210$3,124
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,472
Levothyroxine Sodium175$2,293
Albuterol Sulfate HfaAlbuterol Sulfate47$1,972
Rosuvastatin Calcium112$1,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$78,03864 claims
Lilly USA, LLCTrulicity$314$59,65343 claims
PfizerEliquis$15$57,67340 claims
GSKTrelegy Ellipta$836$51,97241 claims
MerckJanuvia, Janumet$39$47,91344 claims
Novo NordiskOzempic$379$30,72416 claims
AstraZenecaFarxiga, Breztri Aerosphere$447$26,24028 claims
Johnson & JohnsonXarelto$30$14,47511 claims
AbbVieSynthroid$30$76313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →